PharmTech Drug Digest 11.20
News|Articles|November 19, 2026

What Venglustat’s Approval Means for Rare Disease Developers

Listen
0:00 / 0:00

Key Takeaways

  • First-in-indication approval introduces a brain-penetrant oral small molecule for GD3 neurologic symptoms, distinguishing it mechanistically and clinically from enzyme replacement strategies that primarily address systemic disease.
  • A 52-week head-to-head design versus biweekly IV enzyme replacement in stabilized GD3 patients demonstrated improvement in a combined neurologic endpoint incorporating ataxia and cognitive function assessments.
SHOW MORE

FDA approves venglustat, the first oral therapy for Type 3 Gaucher neurological symptoms.

The FDA approved venglustat (Infilbray) tablets on Nov. 18, 2026, as the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg.1 The approval was granted to Genzyme Corporation, a Sanofi company. Venglustat had received Orphan Drug designation and Priority Review.

GD3 is a rare, inherited condition.1 A deficient or malfunctioning enzyme leaves the body unable to properly break down fatty substances called glucosphingolipids. As these substances build up in organs, tissues, and the brain, patients develop worsening problems with balance, coordination, speech, memory, and thinking. This involvement of the brain and nervous system is what separates GD3 from Type 1 Gaucher disease. Venglustat inhibits glucosylceramide synthase, which reduces the buildup of these substances throughout the body and within the brain.

“For patients with Type 3 Gaucher disease, harmful substances build up in the brain without a way to stop them, but this drug’s ability to cross the blood-brain barrier means it can get to the source of the buildup driving the neurological symptoms,” said Acting FDA Commissioner Kyle Diamantas, in a press release.1 “This approval reflects the FDA’s commitment to advancing therapeutic options for patients with rare diseases and brings an important new treatment to patients and the health care providers who care for them.”

What Did the Pivotal Study Show?

The approval is supported by a randomized, double-blind, multicenter study (NCT05222906)1,2 that enrolled 43 patients aged 12 and older with GD3 whose systemic disease had stabilized on enzyme replacement therapy. Participants received either venglustat orally once daily or intravenous enzyme replacement therapy every 2 weeks for 52 weeks. Effectiveness was measured with two assessments of neurological symptoms, covering ataxia and cognitive function. At week 52, patients on venglustat improved on a combined measure of both assessments compared with patients on enzyme replacement therapy, which was given for the nonneurologic manifestations of GD3.

The most common adverse effects were gastrointestinal symptoms and effects on mood.1 Serious psychiatric risks, including suicidal ideation and behavior, have been reported. Animal studies also pointed to possible clouding of vision in younger patients and harm to fetal development when the drug is taken during pregnancy.

Why Does This Approval Matter?

The approval moves treatment of GD3’s neurological component from a biweekly intravenous biologic to a once-daily oral solid dosage form.1 That shift brings different formulation, scale-up and distribution demands than infusion-based enzyme replacement products. The weight-based pediatric indication may also affect how dose strengths are developed and supplied.

The decision adds to a year of rare disease approvals that are reshaping development and manufacturing strategy.3 Expedited rare disease pathways can require scale-up and supply chain readiness to run alongside clinical development. Manufacturers serving small, geographically dispersed patient populations also need agile, compliant production models.

Venglustat also follows September’s approval of zilganersen for Alexander disease, an intrathecally delivered RNA-targeted therapy dosed quarterly.4 These 2 approvals show the range of delivery strategies, from intrathecal oligonucleotides to brain-penetrant oral small molecules, that regulators are accepting for neurological rare diseases.

What Other Approval Did Sanofi Receive This Week?

Separately, Sanofi announced on Nov. 19, 2026, that the European Commission had approved VaxRabeo (rabies virus inactivated strain Wistar) for pre-exposure and postexposure prophylaxis against rabies in all age groups.5 The approval followed a positive opinion from the EMA’s Committee for Medicinal Products for Human Use on Sept. 17, 2026.

VaxRabeo is produced using Vero cell technology and shares its viral strain with Sanofi’s Verorab and Imovax Rabies vaccines.5 It has a 60-month shelf life and stays stable at temperatures up to 27 °C for 96 hours before reconstitution, it is also formulated to minimize the risk of allergic reactions. In pre-exposure studies, 2- and 3-dose regimens produced protective antibody levels comparable to the existing vaccines in adults and children. In post-exposure studies, 100% of participants given the vaccine intramuscularly reached protective antibody levels. The stability profile is the most relevant point. WHO estimates put rabies in 150 countries, causing approximately 59,000 deaths each year, and approximately 29 million people receive post-exposure vaccination annually.

References

  1. FDA. FDA approves first drug to treat neurological symptoms of type 3 Gaucher disease. News Release. November 18, 2026. Accessed November 19, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease
  2. Study to evaluate the efficacy and safety of venglustat in adult and pediatric patients with Gaucher disease type 3 (LEAP2MONO). ClinicalTrials.gov. Identifier: NCT05222906. Accessed November 19, 2026. https://clinicaltrials.gov/study/NCT05222906
  3. Zubulake Z. The current state of rare disease approvals. Pharmaceutical Technology. May 18, 2026. Accessed November 19, 2026. https://www.pharmtech.com/view/rare-disease-approvals
  4. Zubulake Z. What an Alexander disease approval means for RNA developers. Pharmaceutical Technology. September 4, 2026. Accessed November 19, 2026. https://www.pharmtech.com/view/what-an-alexander-disease-approval-means-for-rna-developers
  5. Sanofi. Sanofi’s next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages. News release. November 19, 2026. Accessed November 19, 2026. https://www.sanofi.com/en/media-room/press-releases/2026/2026-11-19-06-00-00-3406292


Related to this article